

14. Mackowiak PA, Durack DT. Fever of unknown origin. In: Bennett JE, Dolin R, Blaser MJ, Parta M (eds). *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 8th ed. Elsevier Saunders: Philadelphia 2015: 721–729.
15. Bottieau E, Clerinx J, Van den Enden E, et al. Fever after a stay in the tropics: diagnostic predictors of the leading tropical conditions. *Medicine (Baltimore)* 2007; 86(1): 18–25.
16. Zenone T. Fever of unknown origin in rheumatic diseases. *Infect Dis Clin North Am* 2007; 21(4): 1115–1135.
17. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still's disease. *Autoimmun Rev* 2014; 13(7): 708–722.
18. Foggo V, Cavenagh J. Malignant causes of fever of unknown origin. *Clin Med (Lond)* 2015; 15(3): 292–294.
19. Chang JC, Gross HM. Utility of naproxen in the differential diagnosis of fever of undetermined origin in patients with cancer. *Am J Med* 1984; 76: 597–603.
20. Roush MK, Nelson KM. Understanding drug-induced febrile reactions. *Am Pharm* 1993; 33(10): 39–42.
21. Mackowiak PA. Drug fever: mechanisms, maxims and misconceptions. *Am J Med Sci*. 1987; 294(4): 275–286.
22. Ochi H, Wada K, Okada H, et al. The persistence of drug-induced fever by teicoplanin--a case report. *Int J Clin Pharmacol Ther*. 2011; 49(5): 339–343.
23. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. *N Engl J Med* 1994; 331(19): 1272–1285.
24. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. *J Am Acad Dermatol* 2013; 68(5): 693.e1–e14.
25. Cunha BA. Fever of unknown origin: focused diagnostic approach based on clinical clues from the history, physical examination, and laboratory tests. *Infect Dis Clin North Am* 2007; 21(4): 1137–1187.
26. Kovačevićová M, Švestková S. Retikulární exantémy – patofyziologie, etiopatogeneze, klasifikace. *Čes-slov Derm* 2012; 87(6): 211–219.
27. Fogo A, du Vivier A. The cutaneous manifestations of haematological malignancy. *Clin Med (Lond)* 2009; 9(4): 366–370.
28. Shmerling RH. Evaluation of the adult with polyarticular pain. UpToDate 2020. [cit. 2020-06-25]. Dostupné z www.uptodate.com/contents/evaluation-of-the-adult-with-polyarticular-pain.
29. Gaddey HL, Riegel AM. Unexplained Lymphadenopathy: Evaluation and Differential Diagnosis. *Am Fam Physician* 2016; 94(11): 896–903.
30. Bona R. Evaluation of splenomegaly and other splenic disorders in adults. UpToDate 2020. [cit. 2020-06-25]. Dostupné z www.uptodate.com/contents/evaluation-of-splenomegaly-and-other-splenic-disorders-in-adults.
31. Curry MP, Bonder A. Overview of the evaluation of hepatomegaly in adults. UpToDate. 2020 [cited 2020 Jun 25]. Dostupné z www.uptodate.com/contents/overview-of-the-evaluation-of-hepatomegaly-in-adults.
32. Loughrey PB, Armstrong D, Lockhart CJ. Classical eye signs in bacterial endocarditis. *QJM* 2015; 108(11): 909–910.
33. Ruddy SM, Bergstrom R, Tivakaran VS. Roth Spots. *StatPearls* 2020. [cit. 2020-06-25]. Dostupné z www.ncbi.nlm.nih.gov/books/NBK482446/.
34. Shane E. Diagnostic approach to hypercalcemia. UpToDate 2020. [cit. 2020-07-12]. Dostupné z www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia.
35. Bray C, Bell LN, Liang H, et al. Erythrocyte Sedimentation Rate and C-reactive Protein Measurements and Their Relevance in Clinical Medicine. *WMJ* 2016; 115(6): 317–321.
36. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. *Clin Infect Dis* 2004; 39(2): 206–217.
37. Maruna P. *Proteiny akutní fáze*. 1. vydání. Maxdorf: Praha 2004.
38. Erez A, Shental O, Tchebiner JZ, et al. Diagnostic and prognostic value of very high serum lactate dehydrogenase in admitted medical patients. *Isr Med Assoc J* 2014; 16(7): 439–443.
39. Li L, Dong M, Wang XG. The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator. *Chin Med J (Engl)* 2016; 129(4): 448–455.
40. Castro C, Gourley M. Diagnostic testing and interpretation of tests for autoimmunity. *J Allergy Clin Immunol* 2010; 125(Suppl 2): S238–S247.
41. Dasgupta A, Wahed A. Protein Electrophoresis and Immunofixation. In Dasgupta A, Wahed A (authors). *Clinical chemistry, immunology and laboratory quality control: A comprehensive review for board preparation, certification and clinical practice*. 1st ed. Elsevier: Amsterdam 2014: 391–405.
42. Casulo C, Maragulia J, Zelenetz AD. Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections. *Clin Lymphoma Myeloma Leuk* 2013; 13(2): 106–111.
43. De Angelis F, Tosti ME, Capria S, et al. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study. *Leuk Res* 2015; 39(12): 1382–1388.
44. Guyomard S, Salles G, Coudurier M et al. Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma. *Br J Haematol* 2003; 123(1): 90–99.
45. Coburn B, Morris AM, Tomlinson G, et al. Does this adult patient with suspected bacteremia require blood cultures? *JAMA* 2012; 308(5): 502–511.
46. Werner M, Andersson R, Olaison L, et al. A clinical study of culture-negative endocarditis. *Medicine (Baltimore)* 2003; 82(4): 263–273.
47. Dibble EH, Yoo DC, Noto RB. Role of PET/CT in Workup of Fever without a Source. *Radiographics* 2016; 36(4): 1166–1177.
48. Vilacosta I, Olmos C, de Agustín A, et al. The diagnostic ability of echocardiography for infective endocarditis and its associated complications. *Expert Rev Cardiovasc Ther* 2015; 13(11): 1225–1236.
49. Censullo A, Vijayan T. Using Nuclear Medicine Imaging Wisely in Diagnosing Infectious Diseases. *Open Forum Infect Dis* 2017; 4(1): ofx011. Dostupné z DOI: <https://doi.org/10.1093/ofid/ofx011>.
50. Hung BT, Wang PW, Su YJ, et al. The efficacy of 18 F-FDG PET/CT and 67Ga SPECT/CT in diagnosing fever of unknown origin. *Int J Infect Dis* 2017; 62: 10–17.
51. Seshadri N, Sonoda LI, Lever AM, et al. Superiority of 18F-FDG PET compared to 111In-labelled leucocyte scintigraphy in the evaluation of fever of unknown origin. *J Infect* 2012; 65(1): 71–79.
52. Roth AR, Basello GM. Approach to the adult patient with fever of unknown origin. *Am Fam Physician* 2003; 68(11): 2223–2228.
53. Tan Y, Liu X, Shi X. Clinical features and outcomes of patients with fever of unknown origin: a retrospective study. *BMC Infect Dis* 2019; 19(1): 198.